細菌性結膜炎治療薬の世界市場:フルオロキノロン、アミノグリコシド、マクロライド

◆英語タイトル:Global Bacterial Conjunctivitis Drugs Market 2016-2020
◆商品コード:IRTNTR8368
◆発行会社(調査会社):Technavio
◆発行日:2016年2月17日
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、細菌性結膜炎治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、細菌性結膜炎治療薬の世界市場規模及び予測、薬剤種類別分析、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況などの情報をお届けいたします。
【レポートの概要】

About Bacterial Conjunctivitis Drugs

Bacterial conjunctivitis, which affects either one or both the eyes, is an extremely contagious eye condition wherein the conjunctiva is infected. Staphylococci, streptococci, gonococci, and Chlamydia are some of the causative agents of bacterial conjunctivitis. Extremely pathogenic bacteria such as Chlamydia trachomatis and Neisseria gonorrhea cause severe bacterial conjunctivitis. Antibiotics help in eradicating the microbes, resulting in faster clearance of the symptoms. Broad-spectrum antibiotics such as Besivance, Zymaxid, Maxitrol, and AzaSite, in the form of antibiotic pills, ointment, or eye drops help treat the infection. Fluoroquinolones, macrolides, aminoglycosides, and phenicols are among the different classes of antibiotics that are commonly prescribed to treat the condition.

Technavio’s analysts forecast the global bacterial conjunctivitis drugs market to grow at a CAGR of 2.77% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global bacterial conjunctivitis drugs market for 2015-2020. To calculate the market size, it considers revenue generated from the sales of branded and generic drugs along with over-the-counter (OTC) drugs used to treat bacterial conjunctivitis.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Bacterial Conjunctivitis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Akorn
• Alcon
• Allergan
• Bausch & Lomb

[Other prominent vendors]
• Bayer
• Daiichi Sankyo
• F. Hoffmann-La Roche
• InSite Vision
• Merck
• Nicox
• Novartis
• Perrigo
• Pfizer
• Santen Pharmaceutical
• Shire
• Valeant Pharmaceuticals

[Market driver]
• Rising awareness about infections
• For a full, detailed list, view our report

[Market challenge]
• Patent expiry of drugs
• For a full, detailed list, view our report

[Market trend]
• Patient assistance programs
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Overview: Bacterial conjunctivitis
• Conjunctivitis
• Bacterial conjunctivitis
• Signs and symptoms
• Diagnosis
• Management
• Economic burden

PART 06: Pipeline analysis
• FST-100
• AzaSite Xtra (ISV-405)

PART 07: Antimicrobial resistance
• Initiatives to improve innovation of antibiotics

PART 08: Legislation relating to antibiotic use in US

PART 09: Market landscape
• Market overview
• Market size and forecast
• Bacterial conjunctivitis drugs market in US
• Five forces analysis

PART 10: Market segmentation by drug class
• Fluoroquinolones
• Aminoglycosides
• Macrolides
• Other

PART 11: Geographical segmentation
• Global bacterial conjunctivitis drugs market by geography 2015-2020
• Bacterial conjunctivitis drugs market in Americas
• Bacterial conjunctivitis drugs market in EMEA
• Bacterial conjunctivitis drugs market in APAC

PART 12: Market drivers
• Rising awareness about infection
• Development of multidrug-resistant variants
• Prevalence of bacterial conjunctivitis

PART 13: Impact of drivers

PART 14: Market challenges
• Patent expiry of drugs
• Contentment with existing therapies
• Adverse effects and limited efficacy of drugs
• Weak R&D of drugs

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Strategic alliances and M&A
• Use of combination therapies
• Patient assistance programs

PART 17: Vendor landscape
• Competitive scenario
• Akorn
• Alcon
• Allergan
• Bausch & Lomb
• Other prominent vendors

PART 18: Appendix
• List of abbreviations

PART 19: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Types of conjunctivitis
Exhibit 03: Types of bacterial conjunctivitis
Exhibit 04: Signs and symptoms of bacterial conjunctivitis
Exhibit 05: Drugs used to treat conjunctivitis
Exhibit 06: Global bacterial conjunctivitis drugs market: Pipeline portfolio
Exhibit 07: Causes of antimicrobial resistance
Exhibit 08: Initiatives improving antibiotic innovation
Exhibit 09: Legislation relating to antibiotic use in US
Exhibit 10: Global bacterial conjunctivitis drugs market 2015-2020 ($ billions)
Exhibit 11: Snapshot of global bacterial conjunctivitis drugs market
Exhibit 12: Percentage share of bacterial conjunctivitis drugs market in US
Exhibit 13: Bacterial conjunctivitis drugs market in US 2015-2020 ($ millions)
Exhibit 14: Five forces analysis
Exhibit 15: Global bacterial conjunctivitis drugs market by drug class
Exhibit 16: Global bacterial conjunctivitis drugs market by geography 2015
Exhibit 17: Global bacterial conjunctivitis drugs market by geography 2015-2020 ($ billions)
Exhibit 18: Bacterial conjunctivitis drugs market in Americas 2015-2020 ($ millions)
Exhibit 19: Bacterial conjunctivitis drugs market in EMEA 2015-2020 ($ millions)
Exhibit 20: Bacterial conjunctivitis drugs market in APAC 2015-2020 ($ millions)
Exhibit 21: Global bacterial conjunctivitis drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 22: Key drivers
Exhibit 23: Impact of drivers
Exhibit 24: Key challenges
Exhibit 25: Impact of drivers and challenges
Exhibit 26: Key trends
Exhibit 27: Akorn: YoY growth and revenues in ophthalmic segment 2011-2013 ($ millions)
Exhibit 28: Akorn: Key takeaways
Exhibit 29: Business segmentation by revenue 2014
Exhibit 30: Alcon: YoY growth and revenue generated from sales of ophthalmic products 2011-2014 ($ billions)
Exhibit 31: Alcon: Key takeaways
Exhibit 32: Allergan: Key takeaways
Exhibit 33: Bausch & Lomb: Key takeaways



【掲載企業】

Akorn, Alcon, Allergan and Bausch & Lomb, Bayer, Daiichi Sankyo, F. Hoffmann-La Roche, InSite Vision, Merck, Nicox, Novartis, Perrigo, Pfizer, Santen Pharmaceutical, Shire, Valeant Pharmaceuticals.

【レポートのキーワード】

細菌性結膜炎、治療薬、医薬品、フルオロキノロン、アミノグリコシド、マクロライド

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[細菌性結膜炎治療薬の世界市場:フルオロキノロン、アミノグリコシド、マクロライド]販売に関する免責事項
★調査レポート[細菌性結膜炎治療薬の世界市場:フルオロキノロン、アミノグリコシド、マクロライド]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆